Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer
OncLive - 18 Apr 2025Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer ...
dostarlimab
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Cancer Network - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
Rectal Cancer Disappears After Experimental Use of Immunotherapy, Now an FDA Designated Breakthrough Therapy
Memorial Sloan Kettering Cancer Center - 16 Dec 2024Rectal Cancer Disappears After Experimental Use of Immunotherapy, Now an FDA Designated Breakthrough Therapy ...
Imfinzi, Keytruda Approved for Some Endometrial Cancers
National Cancer Institute (.gov) - 06 Aug 2024Imfinzi, Keytruda Approved for Some Endometrial Cancers ...
Immunostimulatory antibodies overview.
ResearchGate - 21 Apr 2025Immunostimulatory antibodies overview. ...
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
Nature - 27 Feb 2025CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours ...
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer
OncLive - 26 Mar 2025Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
Cancer Network - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
Cancer Network - 16 Dec 2024Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
OncLive - 18 Dec 2024FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer ...
Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer
OncLive - 18 Mar 2025Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer ...
Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC
OncLive - 08 Nov 2024Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC ...
Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer
OncLive - 20 Dec 2024Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer ...
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer
OncLive - 07 Nov 2024Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer ...
Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC
OncLive - 14 Sep 2024Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC ...